Hypercholesterolemia
Conditions
Interventions
Pitavastatin group: administration of 2mg pitavastatin once a day for 12 weeks.
Atorvastatin group: administration of 10mg atorvastatin once a day for 12 weeks.
Sponsors
Jikei University Kashiwa Hospital
Jikei University School Aoto Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Hypercholesterolemia or familial hypercholesterolemia. (2)Inpatients or outpatients. (3)Men aged 20 or older, or postmenopausal women. (4)All patients were fully informed and gave written informed consent.
Exclusion criteria
Exclusion criteria: (1)Hypersensitivity for statin treatment. (2)Hepatic disorder (AST or ALT >=100 IU/L), biliary atresia, or suspected hepatic metabolism disorders (acute hepatitis, acute exacerbation of chronic hepatitis, liver cirrhosis, liver cancer, and jaundice). (3)Renal disorder (serum creatinine >= 1.5mg/dL). (4)Receiving cyclosporine. (5)Receiving probucol. (6)Receiving tocopherol. (7)Receiving hormone replacement therapy. (8)Uncontrolled hypothyroidism. (9)Pregnant women, women who may be pregnant, and breast-feeding women. (10)Patients who were judged unsuitable by their doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| (1)Change and percent change in oxidized Lp(a) lipoprotein. (2)Change and percent change in oxidized LDL. | — |
Secondary
| Measure | Time frame |
|---|---|
| (1)Change and percent change in TC, LDL-C, TG and HDL-C. (2)Change and percent change in apo A-1 and apo B. (3)Change and percent change in Lp(a) protein and RLP-C. (4)Change and percent change in Mg. (5)Change of various serum lipoprotein cholesterol by HPLC. (6)Change and percent change in vitamin E. (7)Change and percent change in MDA-LDL. (8)Change and percent change in adiponectin. (9)Change and percent change in small dense LDL. (10)Change and percent change in oxidized HDL. | — |
Countries
Japan
Contacts
Public ContactHiroshi Yoshida
Jikei University Kashiwa Hospital Department of Laboratory Medicine
Outcome results
None listed